Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,185 Cr
Revenue (TTM)
₹314 Cr
Net Profit (TTM)
₹41 Cr
ROE
9.5 %
ROCE
9.9 %
P/E Ratio
28.9
P/B Ratio
3.4
Industry P/E
63.57
EV/EBITDA
17.9
Div. Yield
0.5 %
Debt to Equity
0.7
Book Value
₹406.6
EPS
₹48.1
Face value
10
Shares outstanding
8,506,865
CFO
₹378.20 Cr
EBITDA
₹538.37 Cr
Net Profit
₹288.94 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hester Biosciences
| -12.8 | -11.2 | -12.0 | -0.6 | -6.7 | -4.7 | 12.0 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Hester Biosciences
| -33.1 | 64.5 | -18.6 | -29.2 | 50.0 | 17.7 | 24.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hester Biosciences
|
1,395.0 | 1,184.8 | 314.4 | 36.7 | 17.3 | 12.6 | 28.9 | 3.4 |
| 2,399.8 | 19,696.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 68.6 | 13.0 | |
| 2,904.7 | 36,283.8 | 5,201.6 | 1,014.6 | 22.9 | 25 | 35.8 | 7.9 | |
| 8,321.0 | 20,761.1 | 2,177.5 | 200.9 | 11.3 | 26.5 | 103.3 | 25.0 | |
| 1,478.2 | 28,010.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32.2 | 5.6 | |
| 2,138.6 | 34,607.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.9 | 8.6 | |
| 2,183.8 | 1,351.3 | 446.9 | 35.1 | 8.7 | 12 | 38.5 | 4.3 | |
| 4,773.5 | 21,828.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.6 | 5.5 | |
| 188.4 | 8,232.5 | 2,125.5 | 96.1 | 10.6 | 13.3 | 107.2 | 9.2 | |
| 1,176.2 | 19,123.7 | 3,151.0 | -10.0 | 8.4 | 2.5 | 869.3 | 4.1 |
Companies with less institutional holdings
4 min read•By Jugal Harpalani
1 min read•By Research Desk
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines... for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India. Read more
Incorporated
1987
Chairman
Bhupendra Gandhi
Managing Director
Rajiv Gandhi
Headquarters
Mehsana, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Hester Biosciences Ltd is ₹1,395.00 (NSE) and ₹1,392.75 (BSE) as of 20-Mar-2026 IST. Hester Biosciences Ltd has given a return of -6.69% in the last 3 years.
The P/E ratio of Hester Biosciences Ltd is 28.93 times as on 20-Mar-2026, a 54 discount to its peers’ median range of 63.57 times.
The P/B ratio of Hester Biosciences Ltd is 3.43 times as on 20-Mar-2026, a 66 discount to its peers’ median range of 10.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
38.81
|
3.39
|
|
2024
|
62.57
|
4.05
|
|
2023
|
48.58
|
4.62
|
|
2022
|
58.75
|
8.88
|
|
2021
|
47.36
|
7.14
|
The 52-week high and low of Hester Biosciences Ltd are Rs 2,350.00 and Rs 1,242.95 as of 21-Mar-2026.
Hester Biosciences Ltd has a market capitalisation of ₹ 1,185 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Hester Biosciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-27.90
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.